Literature DB >> 20207497

Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.

Paul L Nguyen1, Ronald C Chen, Karen E Hoffman, Alexei Trofimov, Jason A Efstathiou, John J Coen, William U Shipley, Anthony L Zietman, James A Talcott.   

Abstract

PURPOSE: We examined whether rectal dose-volume histogram (DVH) parameters were associated with long-term patient-reported gastrointestinal (GI) quality of life (QOL) after conventional (70.2 GyE) or high-dose (79.2 GyE) radiation for prostate cancer. METHODS AND MATERIALS: Of 64 men with localized prostate cancer alive with a minimum 7-year follow-up after treatment as part of a randomized trial with either 70.2 GyE or 79.2 GyE of external beam radiation at Massachusetts General Hospital, 56 men (88%) returned a QOL questionnaire, and 50 of those men had DVH information. The DVH parameters of the anterior rectal wall were correlated with patient-reported long-term GI QOL using Pearson correlation and t tests.
RESULTS: There was a trend toward an association between increased long-term GI dysfunction and higher V60 (p = 0.07), V65 (p = 0.06), V70 (p = 0.09), and V75 (p = 0.09). When dichotomized by their medians, a V60 > 54% (p = 0.04), V70 > 44% (p = 0.06), and V75 > 39% (p = 0.06) were associated with increased long-term GI dysfunction. There was no difference in long-term GI dysfunction between men on the conventional vs. high-dose arms (p = 0.49).
CONCLUSIONS: Dose-volume histogram parameters of the anterior rectal wall were associated with long-term patient-reported GI QOL after prostate radiation, whereas the dose prescribed to the prostate was not, suggesting that DVH constraints, rather than total prescribed dose, may have the greatest impact on long-term bowel dysfunction, and therefore that continued dose escalation may be feasible if appropriate dose-volume constraints are met.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20207497     DOI: 10.1016/j.ijrobp.2009.09.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Authors:  Phillip J Gray; Jonathan J Paly; Beow Y Yeap; Martin G Sanda; Howard M Sandler; Jeff M Michalski; James A Talcott; John J Coen; Daniel A Hamstra; William U Shipley; Stephen M Hahn; Anthony L Zietman; Justin E Bekelman; Jason A Efstathiou
Journal:  Cancer       Date:  2013-02-22       Impact factor: 6.860

Review 2.  Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

3.  Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.

Authors:  Hua-chun Luo; Li-ping Cheng; Hui-hua Cheng; Zhi-chao Fu; Shao-guang Liao; Dong-shi Li; Wen-fa Zheng; Gui-shan Lin; Jin-feng Zhu; Jian-feng Xu; Qin Yin; Qing-yang Yu
Journal:  Med Oncol       Date:  2014-05-22       Impact factor: 3.064

4.  Dosimetric impact in the dose-volume histograms of rectal and vesical wall contouring in prostate cancer IMRT treatments.

Authors:  Laura Gómez; Carlos Andrés; Antonio Ruiz
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-21

5.  Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor
Journal:  Acta Oncol       Date:  2017-09-08       Impact factor: 4.089

6.  Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.

Authors:  Thomas J Pugh; Mark F Munsell; Seungtaek Choi; Quyhn Nhu Nguyen; Benson Mathai; X Ron Zhu; Narayan Sahoo; Michael Gillin; Jennifer L Johnson; Richard A Amos; Lei Dong; Usama Mahmood; Deborah A Kuban; Steven J Frank; Karen E Hoffman; Sean E McGuire; Andrew K Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-15       Impact factor: 7.038

7.  Association between EBRT dose volume histograms and quality of life in prostate cancer patients.

Authors:  Anna Boladeras; Ferran Ferrer; Valentin Navarro; Rodolfo De Blas; Oriol Cunillera; David Mateo; Cristina Gutierrez; Evelyn Martinez; Salvador Villà; Joan Pera; Montse Ferrer; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

8.  Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.

Authors:  James R Broughman; Ramsankar Basak; Matthew E Nielsen; Bryce B Reeve; Deborah S Usinger; Kiayni C Spearman; Paul A Godley; Ronald C Chen
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

9.  Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study.

Authors:  Eliahu Gez; Shmuel Cytron; Rahamin Ben Yosef; Daniel London; Benjamin W Corn; Shlomi Alani; Giovanni Scarzello; Fabrizio Dal Moro; Guido Sotti; Filiberto Zattoni; Ike Koziol; Taryn Torre; Matthew Bassignani; Shalom Kalnicki; Reza Ghavamian; Dukagjin Blakaj; Mitchell Anscher; Martin Sommerauer; Dieter Jocham; Corinna Melchert; Stefan Huttenlocher; Gyoergy Kovacs; Madhur Garg
Journal:  Radiat Oncol       Date:  2013-04-23       Impact factor: 3.481

10.  Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy.

Authors:  Sravana K Chennupati; Charles A Pelizzari; Rangesh Kunnavakkam; Stanley L Liauw
Journal:  Cancer Med       Date:  2014-05-06       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.